Advances in Alzheimer’s Disease: Prevention, Diagnosis and Treatment
Deadline for manuscript submissions: 15 May 2024 | Viewed by 4494
2. Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Carlos III Institute of Health, Madrid, Spain
Interests: Alzheimer’s disease; neurological diseases; neurodegenerative diseases; neurodegeneration; neuroimaging; brain diseases; neurobiology; clinical neurology; mild cognitive impairment; molecular neuroscience
Interests: clinical neuropsychology; neuropsychological assessment memory; neurological diseases; behavioral neuroscience; neurodegeneration neuroscience; Alzheimer’s disease; pharmaceutical development; neurology
Interests: aging; dementia; mild cognitive impairment; memory; neuropsychology; Alzheimer’s disease; gerontology; health psychology; cognition disorders; clinical neuropsychology
Special Issues, Collections and Topics in MDPI journals
Alzheimer’s disease (AD) and other related progressive dementias result in significant medical, social and economic impact and are of great concern to the elderly population and their families. In the medical field, this concern is rightly justified. After more than 50 years of expensive research, the early identification of AD and even its nosological definition still presents difficulties, and the main therapeutic investments dedicated to removing beta-amyloid or tau deposits in the brain have been discouraging. The good news is that controlling the environmental risk factors for dementia (lifestyle, lowering blood pressure, physical exercise, and others) can decrease the incidence of dementia and AD in developed countries.
In this Special Issue, we aim to present a state-of-the art revision of several aspects of dementia and AD: nosological concept, clinical diagnosis (AD and mild cognitive impairment) with psychological, biomarkers, and neuroimaging aids, and main neuropathological data. AD therapy and prevention will also be updated.
We invite the readers of JCM to send articles on hot controversies about this subject, e.g., aging, immunity, diabetes, gut microbiome, nutrition, potential infectious agents, informal therapies, and chronic family and institutional care, in contributing toward providing a valuable update on this cumbersome disorder.
Prof. Dr. Félix P. Bermejo-Pareja
Dr. Teodoro Del-Ser
Prof. Dr. Israel Contador Castillo
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Alzheimer’s disease
- dementia, neurological diseases
- neurodegenerative diseases
- brain diseases
- clinical neurology
- mild cognitive impairment
- molecular neuroscience